203 Survodutide, a novel dual GLP-1/ glucagon RA, significantly reduced body weight and improved metabolic dysfunction-associated steatohepatitis compared to the placebo in phase II trials
Zepbound is not a one-size-fits-all solution, and eligibility depends on individual health assessments and specific weight-related conditions
PlexusDx works with licensed 503A compounding pharmacies to provide tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan, allowing patients to access this dual-mechanism therapy without insurance barriers
Also, in many cases, tirzepatide injections are more affordable than semaglutide
Clinical data suggest that tirzepatide, the active medication in Zepbound, may lead to greater average weight loss compared to semaglutide in certain populations
After 24 h, medium was changed, and after other 48 h, cell extracts were analyzed by western blot or the total RNA was collected